E Michalak et al. Supplementary Material
Supplementary Materials and Methods
Real time qRT-PCR analysis primer sequences.
qRTPCR was performed using the following forward and reverse primers (a kind gift from Drs DCS Huang and KJ Campbell)
gene sense (5’ – 3’) antisense (5’ – 3’)
a1 GTCATACTTGGATGACTTTCACGTG ATTCTCCTGTGTTATTCATTATGAATTCTG
bad AGTATGTTCCAGATCCCAGAGTTTG CCTTGAAGGAACCCTCAAACTCATC
bcl-2 TTATAAGCTGTCACAGAGGGGCTAC GAACTCAAAGAAGGCCACAATCCTC
bcl-xl TGGAGTCAGTTTAGTGATGTCGAAG AGTTTACTCCATCCCGAAAGAGTTC
bim GAGTTGTGACAAGTCAACACAAACC GAAGATAAAGCGTAACAGTTGTAAGATAACC
mcl-1 GAGGAGGAAGAGGACGACCTATACC AGTTTCTGCTAATGGTTCGATGAAG
puma ATGCCTGCCTCACCTTCATCT AGCACAGGATTCACAGTCTGGA
noxa ACTGTGGTTCTGGCGCAGAT TTGAGCACACTCGTCCTTCAA
c-myc CAAATCCTGTACCTCGTCCGATTC CTTCTTGCTCTTCTTCAGAGTCGC
Supplementary Figure Legends
Supplementary Figure 1 Loss of Puma affects some B lymphoid cell subsets in the lymph nodes and spleen of E；-myc mice. Total cellularity and cell subset composition of pre-neoplastic 5-6 week old mice of the indicated genotypes. (A) Numbers of pre-B, virgin and mature B cells in the lymph nodes (axillary, brachial, inguinal pairs) were determined by immunofluorescent staining with surface marker-specific monoclonal antibodies and flow cytometric analysis. Differences between E；-myc transgenic and
non-transgenic mice were significant for all puma genotypes for pre-B cells, as were
Michalak et al
-/-comparisons of virgin B cells for wt vs E；-myc/puma mice and for the decrease in
+/- -/-mature B cells for wt vs E；-myc/pumaand wt vs E；-myc/puma mice (P < 0.005).
For comparisons of E；-myc transgenic mice of the different puma genotypes, all
statistically significant differences are indicated. (B) Similar analysis of the spleen revealed differences between E；-myc and non-transgenic mice of all puma genotypes
(P < 0.005) for pre-B cells and mature B cells and for total cells and virgin B cells for
-/-wt vs E；-myc/puma mice. For comparisons of E；-myc transgenic mice of the
different puma genotypes, all statistically significant differences are shown. Values represent means ? SEM from 5-8 mice of each genotype. * P < 0.05, *** P < 0.005.
Supplementary Figure 2 Impact of Puma loss on survival of E；-myc pro-B cells and
+sIg B cells in culture. (A) Pro-B cells or (B) virgin/mature B cells sorted from the bone marrow of 5-6 week old healthy wt mice or E；-myc mice of the indicated puma
genotypes were cultured in simple medium (no cytokines) or treated with etoposide (1 ；g/mL) for the indicated times. For all experiments cell viability was determined by
--FACS analysis as the percentage of Annexin VPI cells. Values represent means ? SD
of cells from 3-6 mice of each genotype. No statistically significant differences were noted between transgenic genotypes. Similar results were obtained with virgin
hilolohi(sIgMsIgD) and mature (sIgMsIgD) B cells from the spleen (data not shown).
Supplementary Figure 3 Representative immunophenotyping FACS plots of
-/-lymphomas from E；-myc and E；-myc/puma mice. Cell suspensions were prepared
from primary lymphomas and flow cytometric analyses performed after immunofluorescent staining with surface marker-specific monoclonal antibodies.
+-++loLymphomas were classified as (A) B220sIg pro-B/pre-B, (B) B220sIgMsIgD B
Michalak et al
-+cell or (C) “mixed” pre-B/B cell if distinct sIg and sIg B lymphoma populations
Supplementary Figure 4 Loss of Puma affects the numbers of B lymphoid cells in E；-myc mice in the absence of Noxa. (A) White blood cell counts (means ? SEM) of pre-neoplastic 4 week-old mice of the indicated noxa genotypes. Cell counts for E；-
myc mice of each of the noxa genotypes did not differ significantly, but the
differences from their non-transgenic counterparts were highly significant (P < 0.0001). (B) Spleen weights (means ? SEM) of pre-neoplastic 5-6 week-old mice of the indicated noxa genotypes. Differences between non-transgenic and E；-myc or
-/-E；-myc/noxa mice were significant (P < 0.001). Spleen weights of E；-myc and E；-
-/-myc/noxa mice were similar (P = 0.76). (C) B lymphoid cell subset composition of
lymph nodes, peripheral blood and spleen from pre-neoplastic 5-6 week-old mice of the indicated genotypes. Total cellularity and cell subset composition were determined as described in Supplementary Figure 1. For lymph nodes, statistically significant differences in addition to those indicated were noted for total cells and pre-
-/-+/-B cells for E；-myc vs E；-myc/noxapuma mice. For peripheral blood, statistically
significant differences in addition to those indicated were noted for all comparisons
-/-except between E；-myc vs E；-myc/noxa mice. For spleen, statistically significant
differences in addition to those indicated were noted for total cells, virgin B cells and
-/-+/- mature B cells for E；-myc vs E；-myc/noxapumamice and for total cells, pre-B
-/--/--/-cells and virgin B cells for E；-myc/noxa and E；-myc/noxapuma mice
(P < 0.005). Values in (C) represent means ? SEM from 3-7 mice of each genotype. *
P < 0.05, ** P < 0.01, *** P < 0.005.
Michalak et al
Supplementary Figure 5 Loss of Noxa does not enhance the survival of E；-myc
transgenic B lymphoid cells in culture. Pro-B cells (A), pre-B cells (B) or virgin and mature B cells (C) were sorted from the bone marrow of 5-6 week old healthy wt mice or E；-myc mice of the indicated noxa genotypes and cultured in simple medium
(no added cytokines) or treated with etoposide (1 ；g/mL) for the indicated times. Cell
--viability was determined by FACS analysis as the percentage of Annexin VPI cells.
mice of each genotype. Data points represent means ? SEM of cells from 3-6
-/--/-Statistically significant differences noted: E；-myc vs E；-myc/noxapuma and E；-
-/--/--/-myc/noxa vs E；-myc/noxapuma, P < 0.5 for pro-B cells and virgin/mature B cells at 4 hours post etoposide only.
Supplementary Figure 6 Loss of Noxa does not accelerate lymphomagenesis in E；-
myc mice. Kaplan-Meier analysis of tumour-free survival of mice of the indicated
+/-genotypes. Differences in tumour onset between E；-myc and E；-myc/noxa or E；-
-/-myc/noxa mice were not significant (P = 0.18 and P = 0.13, respectively).
Supplementary Figure 7 Western blot analysis of p19Arf expression levels in lymphomas from E；-myc mice of the various puma and noxa genotypes. Western blot
analysis of p19Arf and ;-actin (loading control) on protein isolated from lymphoma suspensions from E；-myc mice of the indicated puma and noxa genotype. Lysates
-/-from p53 mouse embryonic fibroblasts (MEF) or a tumour (E；-myc tumours known
to be positive for p19Arf) were included as positive controls for p19Arf over-expression. Protein size standards in kDa are indicated on the left-hand side.
Michalak et al
Supplementary Figure 8 Assessment of p53 status and function in E；-myc
-lymphomas. (A) Genomic PCR of the Ink4A/arf locus revealed that no E；-myc/puma
/- lymphoma was observed to have a deletion of this gene. Controls: E；-myc
lymphoma cell line known to contain a deletion in the Ink4A/arf locus; spleen from an
-/- Ink4A/arf deficient mouse; E；-myc/p53lymphoma known to retain the Ink4A/arf locus; E；-myc lymphoma known to retain the Ink4A/arf locus. (B) Assessment of p53 status and function in cohorts of E；-myc lymphomas with or without Puma.
*Lymphoma cell lines displayed p53 deficiency-like resistance following in vitro
exposure to etoposide. ND = Not Done.
Michalak et al